Home / Papers / Vaccines and Vaccination

Vaccines and Vaccination

88 Citations2012
M. D'souza
journal unavailable

Preliminary studies conducted in the laboratory with infectious disease vaccines such as TB, typhoid, influenza, pneumonia, meningitis and hepatitis B vaccine antigens suggest that this delivery system is highly suitable for antIGens to be used for protective immunity.

Abstract

We, at the Nanotechnology Laboratory at Mercer University, Atlanta, have developed a platform technology using nanoparticles and microparticles to deliver vaccines by the oral route of administration. This formulation technology enables us to prepare the vaccine particles containing vaccine antigens, without loss of their biological activity during the formulation process. We can also encapsulate multiple antigens, targeting ligands and adjuvants within in the same particle. Using our novel method, the vaccine prepared exists in a dry and stable form. When administered orally, these particles are designed to withstand the acidic environment of the stomach and are targeted to the Peyer’s patches and the gut associated mucosal immune system. Since these vaccines are particulate in nature, they are readily taken up by phagocytic antigen presenting cells (APC’s), such as M cells, dendritic cells and macrophages in the Peyer’s patches of the intestines, resulting in a strong immune response and antibody production. Of particular interest in this formulation is the fact that the particles release the antigen in a slow and sustained manner over a prolonged time period, intracellularly into APC’s, resulting in strong mucosal and systemic immunity after oral administration, without the need for added adjuvants that are typically present in current vaccine preparations. Since no needles are required, for oral vaccines, this method of vaccine delivery is inexpensive and suitable for mass vaccination in the developing world as well as for the developed world. Preliminary studies conducted in our laboratory with infectious disease vaccines such as TB, typhoid, influenza, pneumonia, meningitis and hepatitis B vaccine antigens suggest that this delivery system is highly suitable for antigens to be used for protective immunity. This method of vaccine delivery enables us to address a wide spectrum of vaccines for prophylactic and therapeutic use. Recently, we have been evaluating oral vaccines for cancer such as HPV, melanoma, ovarian, breast and prostate with encouraging results.